Baylis Medical said today that it successfully completed the first Abbott (NYSE:ABT) MitraClip procedure with Baylis’ VersaCross transseptal solution catheter. VersaCross is a left-heart access device designed with an atraumatic radio frequency-tipped pigtail wire to achieve access and then serve as an exchange wire, reducing the number of exchanges throughout the procedure. The MitraClip is designed […]
Abiomed claims win over Abbott’s Thoratec in German patent case
Abiomed (NSDQ:ABMD) today claimed a win in a German patent infringement case brought by Abbott (NYSE:ABT) subsidiary Thoratec. The Danvers, Mass.-based heart pump maker said Germany’s highest court ruled in its favor in a patent challenge dating back to 2015. St. Jude Medical acquired Thoratec in October 2015 and was in turn acquired by Abbott […]
Ambrosia app links Abbott’s FreeStyle Libre with Fitbit wearable
Ambrosia Systems said today that it launched its LinkBlueCon application on the Fitbit and Abbott (NYSE:ABT) FreeStyle Libre smartwatch platforms for glucose monitoring. San Fransisco-based Ambrosia’s LinkBlueCon app is designed to monitor glucose levels and receive notifications when glucose readings are outside the target range, all without the need to go to a clinic. Ambrosia said […]
The 20 largest medical device companies in the world
Consolidations continue to transform the roster of largest medical device companies in the world — as evidenced by the latest Big 100 list at our sister site Medical Design & Outsourcing. Overall, Big 100 companies saw $397.5 billion in sales during their most recent fiscal years, up 3.5% from the previous year. As companies continue to […]
Abbott wins CE Mark for pediatric heart devices
Abbott (NYSE:ABT) said today that it won CE Mark approval for its Masters HP mechanical heart valve and Amplatzer Piccolo occluder. The Masters HP is the world’s smallest mechanical heart valve (15mm) and is designed for implantation in the mitral or aortic position to mimic a healthy heart valve by opening and closing to facilitate blood […]
Abbott, Medtronic ink diabetes pacts with Sanofi, Novo Nordisk
Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) today announced separate data-sharing deals for digital diabetes management solutions. Abbott is partnering with Sanofi (NYSE:SNY) to integrate glucose sensing and insulin delivery to help people manage their diabetes. The two companies plan to develop tools to combine Abbott’s FreeStyle Libre technology with insulin dosing information for smart pens, insulin titration apps and cloud software. […]
Abbott wins FreeStyle Libre reimbursement in Ontario, Quebec
Abbott (NYSE:ABT) said today that it has won public reimbursement in Ontario and Quebec for its FreeStyle Libre sensor-based glucose monitoring system — the first of its kind listed by any provincial health plan in Canada. FreeStyle Libre is designed to monitor glucose levels with a small sensor on the back of the upper arm […]
Trial will pit Nobles Medical’s PFO tech against Abbott’s for stroke reduction
The FDA has granted Nobles Medical Technologies II approval to conduct a prospective pivotal clinical trial for the expanded indication of patent foramen ovale (PFO) closure for reduction of recurrent ischemic stroke, according to the company. The FDA cleared the NobleStitch EL for cardiovascular suturing in April 2017. It was CE marked in Europe for […]
Abbott launches U.S. pivotal trial for TriClip tricuspid repair device
Abbott (NYSE:ABT) said today that it’s launching another study of its TriClip tricuspid valve repair device, this time aimed at winning U.S. regulatory approval. The five-year, 700-patient Triluminate pivotal trial, under an investigational device exemption from the FDA, is the first such study of a transcatheter, non-surgical treatment for patients with severe tricuspid regurgitation, Abbott […]
ESC Congress: Study shows bariatric surgery can improve cardiac outcomes in Type 2 diabetes
Bariatric or metabolic surgery can significantly lower the risk of major cardiovascular events among patients with Type 2 diabetes and obesity, according to a new clinical study released at the European Society of Cardiology Congress in Paris. The retrospective study followed 13,722 Type 2 diabetes patients who underwent bariatric surgery to lose weight or metabolic […]
Surmodics reaps $10m from Abbott on SurVeil balloon milestone
Surmodics (NSDQ:SRDX) said today that it’s due for a $10 million milestone payment from Abbott (NYSE:ABT) after closing enrollment for the Transcend pivotal trial of its SurVeil drug-coated balloon for treating peripheral artery disease. Abbott in February 2018 paid $25 million up front for the global commercialization rights to the SurVeil device, which uses a proprietary […]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 69
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube